At a glance: KPV is a tiny peptide (lysine-proline-valine) cut from the anti-inflammatory hormone alpha-MSH. It reduced gut inflammation in mice and calmed inflammatory signals in lab skin models, but FDA's 2026 review found no human data at all: no trials, no case reports, no pharmacokinetic studies. It is not FDA-approved. An advisory panel voted 8 to 6 to recommend it for compounding in July 2026, against FDA staff advice; that vote is non-binding.
What is KPV?
KPV is a tripeptide: three amino acids, lysine (K), proline (P) and valine (V). It is the tail end of alpha-melanocyte-stimulating hormone (alpha-MSH), a natural hormone that, among other things, calms inflammation and stimulates skin pigment.
Researchers found that this short fragment keeps much of alpha-MSH's anti-inflammatory activity without its tanning effect. Products are lab-made.
How does KPV work?
- Enters gut cells through PepT1, a transporter in the intestinal lining that carries small peptides, which is part of why oral KPV reached inflamed gut tissue in mouse studies
- Dampens NF-kB, a master switch inside cells that turns on many inflammatory genes
- Lowers inflammatory cytokines, the signaling molecules that drive inflammation
- Exact molecular target unknown: FDA's review noted that how KPV produces these effects has not been pinned down
What the research shows so far
| Study | What was tested | Main finding |
|---|---|---|
| Dalmasso et al., Gastroenterology 2008 | Intestinal cells and two mouse models of colitis | KPV entered gut cells via PepT1, reduced inflammatory signaling, and oral KPV reduced colitis in mice |
| Skin cell studies (including 2025) | Human skin cells and 3D lab skin models | Reduced inflammatory signaling and oxidative stress after irritant exposure |
| Human skin permeation (FDA review) | Cadaver skin in a lab | Poor penetration through skin, a problem for topical creams |
| Human studies | None | FDA found no clinical trials, case reports or pharmacokinetic data for any route |
FDA also found no standard toxicology studies (repeat-dose, genetic, reproductive or cancer) for KPV.
Why it gets attention
- Gut inflammation: marketed for inflammatory bowel conditions, leaky gut and digestive issues, based on the mouse colitis data
- Skin conditions: promoted for eczema, psoriasis and wound healing
- "Gentle" reputation: a small natural-hormone fragment that users describe as well tolerated
- Blends and the 2026 FDA vote: it is an ingredient in the KLOW blend and was one of six peptides an FDA panel recommended in July 2026
How it is used
KPV is sold as oral capsules (aimed at the gut), topical creams (aimed at skin) and injectable or nasal products. The published experiments used different formulations from marketed products, and no standard dose exists for any route. This page does not provide dosing guidance.
What about side effects?
KPV is often described as well tolerated, but no human study has measured its side effects, so their frequency and nature are unknown.
- Immune reactions: FDA flagged immunogenicity and peptide clumping (aggregation) as unassessed risks.
- Product quality: FDA found inconsistent certificates of analysis, no microbial or aggregate testing, and that KPV acetate breaks down under stress conditions. Online products may be mislabeled or non-sterile.
- Long-term safety: unknown.
- Pregnancy and breastfeeding: not studied.
- Gut and skin symptoms need diagnosis: conditions like Crohn's disease, ulcerative colitis and psoriasis have effective approved treatments.
Regulatory status
- Not FDA-approved for any use, by any route.
- In April 2026 FDA removed KPV from its "Category 2" safety-concern list after its nomination was withdrawn. That was not a safety finding.
- FDA reviewed KPV for topical use in wound healing and inflammatory skin conditions and recommended against adding it to the compounding list, citing no human data, unknown safety and poor characterization.
- On July 23, 2026 the advisory committee nonetheless voted 8 to 6, with 1 abstention, to recommend it. The vote is non-binding; FDA would need formal rulemaking, which typically takes a year or more, before compounding is allowed.
- Until then, current rules are unchanged, and "research use only" products are not approved for human use.
The bottom line
KPV is a scientifically interesting anti-inflammatory fragment with encouraging mouse and lab results, especially for gut inflammation. But FDA's own review found no human evidence of any kind, poor skin absorption and unanswered quality questions, and the 2026 advisory vote did not approve it. Anyone with gut or skin inflammation should see a clinician, since effective, well-studied treatments exist.
Frequently asked questions
What is KPV?
A three-amino-acid peptide taken from the end of the alpha-MSH hormone.
How is KPV taken?
Oral, rectal or injected in animal studies; no established human route.
Is KPV FDA approved?
Not approved.
That means no regulator has reviewed its safety, effectiveness or manufacturing quality for this use.
What has research shown about KPV?
- Inflammation in animal models of colitis.
- Anti-inflammatory activity in skin and gut cell studies.
What side effects have been reported?
- Not characterised in humans
Serious or less common risks are listed in the Side Effects section above.
What is still unknown about its safety?
Most of it. KPV has not been through the trials that establish long-term safety in people, and products sold online are made by unregulated labs. Independent testing of online peptides has repeatedly found contents that do not match the label.
References
- FDA: Evaluation of KPV and KPV acetate for the 503A bulks list (July 2026 PCAC briefing). View source
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. View source
- KPV in human keratinocytes and 3D skin models (2025). View source
- HealingMaps: KPV FDA panel vote (July 2026). View source
- AJMC: FDA panel backs 6 peptides for compounding (July 2026). View source
- Rite Aid: KPV overview. View source